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Compassionate use, also called expanded access, provides an important pathway for patients with life-
threatening conditions to gain access to unapproved investigational drugs, biologics and medical devices.
Although the United States (US) and the countries of the Europe Union (EU) have mechanisms that are
associated with the use of unapproved products, as of May 2015 there was no such mechanism in Japan.
Instead, unapproved products are used under a physician's discretion in conjunction with the Japan
Medical Practitioners' Act or Advanced Medical Care B. However, there are some issues and questions to
consider under the current circumstances in Japan as follows: (A) it is difﬁcult for the local regulator to
monitor the use of unapproved products; (B) there is no information collected on the safety of these
products to protect patients; (C) it is difﬁcult to assure the quality of the products; (D) it is difﬁcult for
patients to obtain detailed information about unapproved products and their availability; and (E) it is not
clear who should cover the cost of the unapproved products.
In this paper, we assess the current compassionate use, or expanded access-related mechanisms, of the
US, the EU and Japan in regard to drugs, medical devices and biologics, including human cells and tissue
products, and discuss the beneﬁts and issues of these mechanisms. The purpose of these mechanisms is
principally to save patients with life-threatening condition. However, the information obtained after the
compassionate use is potentially useful to facilitate marketing authorization. In fact, the data from
compassionate use cases are employed in some approval review reports to indicate the product safety.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Compassionate use, also called expanded access, provides an
important pathway for patients with life-threatening conditions to
gain access to unapproved investigational drugs, biologics and
medical devices. According to The European Medicines Agencyedical Engineering and Science, T
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countries of Europe Union (EU) have mechanisms associated with
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tioners' Act or other mechanisms such as Advanced Medical Care B
[2]. However, there are some issues and questions to consider un-
der the current circumstances in Japan, as follows: (A) it is difﬁcult
for the local regulator to monitor the usage of unapproved prod-
ucts; (B) there is no information collected on the safety and efﬁcacy
of these products to protect patients; (C) it is difﬁcult to assure the
quality of the products; (D) it is difﬁcult for patients to obtain
detailed information about unapproved products and their avail-
ability; and (E) it is not clear who should cover the cost of unap-
proved products.
In this paper, we conduct an assessment of the current
compassionate use and expanded access-related mechanisms in
the US, EU and Japan with regard to drugs, medical devices andTable 1
The FDA's expanded access mechanism for drugs.
Category Emergency Use (IND/
protocol)
Individual Patien
protocol)
Regulation 21 CFR 312.305
21 CFR 312.310
21 CFR 312.305
21 CFR 312.310
Safety reporting regulation 21 CFR 312.32
21 CFR 312.310(c) (2)
21 CFR 312.32
21 CFR 312.310(
Common criteria 1) The patient or patients to be treated have a seriou
or satisfactory alternative therapy to diagnose, m
2) The potential patient beneﬁt justiﬁes the potent
context of the disease or condition to be treated
3) Providing the investigational drug for the reque
investigations that could support marketing app
development of the expanded access use.
Additional criteria 1) No time to obtain the
FDA approval by a
written submission.
2) The physician must
determine that the
probable risk to the
person from the
investigational drug is
not greater than the
probable risk from the
disease or condition.
3) FDA must determine
that the patient cannot
obtain the drug under
another IND or protocol.
1) The physic
determine th
probable risk
person from
investigation
not greater th
probable risk
disease or co
2) FDA must
that the patie
obtain the dr
another IND
Population Individual patient Individual patien
When can it be used Before or after clinical trial Before or after c
Prior the FDA approval Required (in case of an
emergency before a written
submission, the FDA may
authorize the emergency
use by telephone)
Required
Charge Patient or donation by
company
Patient or donat
company
Example of products
(ClinicalTrials.gov
identiﬁer)
Tocilizumab
(NCT00862758)
Elotuzumab
(NCT02541643)
The US: The United States, CFR: Code of Federal Regulation, FDA: Food and Drug Admin
Source: 21 CFR 312 Subpart I.
ClinicalTrials.gov by the U.S. National Institutes of Health <https://clinicaltrials.gov/>.biologics, including human cells and tissue products, and discuss
the beneﬁts and issues of these mechanisms.
2. Methods
The information regarding the United States Food and Drug
Administration (FDA) expanded access program for drug, medical
device and biologics was obtained from the relevant FDA website
[3]. The information regarding compassionate use mechanisms in
the EU was obtained from the EMA websites [4]. The information
regarding France's compassionate use programs was obtained from
the French National Agency for Medicines and Health Products
Safety (ANSM) websites [5]. The information regarding Germany's
compassionate use was obtained from the Federal Institute forts (IND/ Intermediate-Size Patient
Populations (IND/protocol)
Treatment (IND/protocol)
21 CFR 312.305
21 CFR 312.315
21 CFR 312.305
21 CFR 312.320
c) (2)
21 CFR 312.32 21 CFR 312.32
s or immediately life-threatening disease or condition, and there is no comparable
onitor, or treat the disease or condition.
ial risks of the treatment use and those potential risks are not unreasonable in the
.
sted use will not interfere with the initiation, conduct, or completion of clinical
roval of the expanded access use or otherwise compromise the potential
ian must
at the
to the
the
al drug is
an the
from the
ndition.
determine
nt cannot
ug under
or protocol.
1) Enough evidence that
the drug is safe at the
dose and duration
proposed to justify a
clinical trial of the drug
in the approximate
number of patients
expected to receive the
drug.
2) At least preliminary
clinical evidence of
effectiveness of the
drug, or of a plausible
pharmacologic effect of
the drug to make
expanded access use a
reasonable therapeutic
option in the anticipated
patient population.
1) Trial status. (i) The drug
is being investigated in
a controlled clinical trial
under an IND or (ii) all
clinical trials of the drug
have been completed
2) Marketing status. The
sponsor is actively
pursuing marketing
approval of the drug.
3) Evidence. (i) Sufﬁcient
clinical evidence of
safety and effectiveness
or (ii) the available
scientiﬁc evidence,
taken as a whole,
provides a reasonable
basis to conclude that
the investigational drug
may be effective and
would not expose
patients to an
unreasonable and
signiﬁcant risk of illness
or injury.
t Group Group
linical trial The drug not being
developed, the drug being
studied in a clinical trial or
approved.
After ordinarily phase 3
trials or compelling data
from completed phase 2
trials
Required Required
ion by Patient or donation by
company
Patient or donation by
company
RAVICTI (NCT02094222) Generex Oral-lyn™ (buccal
insulin spray)
(NCT00948493)
istration, IND: Investigational New Drug.
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Medizinprodukte, BfArM) website [6]. The information regarding of
the United Kingdom (UK)'s compassionate use was obtained from
the Medicines & Healthcare products Regulatory Agency (MHRA)
[7]. Other information was obtained from the literature [8,9].3. Results
3.1. Overview of the compassionate use of drugs
The FDA expanded access programs for drugs are summarized in
Table 1 [9e11]. Within the FDA, there are four main mechanisms
used e “Emergency Use Investigational New Drug (IND)/protocol,”
“Individual Patients IND/protocol,” “Intermediate-Size Patient
Populations IND/protocol” and “Treatment IND/protocol,”
depending on the urgency, the number of patients whom the
product is applied to, when it can be used and the necessity of prior
FDA approval. Each mechanism has two types of submission,Table 2
The EU's compassionate use mechanism for drugs.
Country (regulator) France (ANSM) France (ANSM)
Category Nominative ATU Cohort ATU
Safety reporting
regulation
Articles R. 5121-150 et seq.
of the French code of Public
Health
Articles R. 5121-150 et seq
of the French code of Publ
Health
Regulation  DIRECTIVE 2001/83/EC
Article 5
 Article L.5121-12 of the
French Public Health
Code
 REGULATION (EC) N
726/2004 Article 83
 Article L.5121-12 of th
French Public Health
Code
Criteria 1) For the treatment of
serious or rare diseases.
2) In the absence of a
suitable therapeutic
alternative (with a
Marketing
Authorization) available
in France.
3) When there is presumed
to be a positive beneﬁt/
risk.
1) For the treatment o
serious or rare disease
2) In the absence of
suitable therapeutic
alternative (with a
Marketing
Authorization) availabl
in France.
3) When there is presume
to be a positive beneﬁt
risk.
Population Individual patient Group
When can it be
used
Efﬁcacy/safety ratio
presumed to be favourable
for these patients based on
available data.
Efﬁcacy and safety are
strongly presumed.
Prior regulator
approval
Required Required
Charge Country health care system
or donation by company.
Country health care system
or donation by company.
Examples of
products
MYLOTARG (gemtuzumab
ozogamicin)
LENVIMA (Lenvatinib)
The EU: The European Union, EEA: The European Economic Area, EMA: EuropeanMedicin
BfArM: The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzn
Healthcare Products Regulatory Agency, ATU: Authorisation Temporaire d' Utilisation (T
France source: Notice to applicants for Temporary Authorisation for Use (AT
cadfbcf9594614d59c8915670853a28b.pdf.
Temporary Authorisations for Use (ATU): http://agence-tst.ansm.sante.fr/html/pdf/5/atu
German source: http://www.bfarm.de/EN/Drugs/licensing/clinicalTrials/compUse/_node
http://www.bfarm.de/SharedDocs/Downloads/EN/Drugs/licensing/clinicalTrials/compUse
UK source: https://www.gov.uk/government/uploads/system/uploads/attachment_data/
UK charge and an example of product: http://www.nhsbsa.nhs.uk/PrescriptionServices/3
nhsbsa.nhs.uk/PrescriptionServices/Documents/PPD%20Drug%20Tariff/October_2015.pdf
MYLOTARG source: http://ansm.sante.fr/content/download/65249/835163/version/3/ﬁle
LENVIMA source: http://ansm.sante.fr/Activites/Autorisations-temporaires-d-utilisation-
Zanamivir i.v source: http://www.bfarm.de/DE/Arzneimittel/zul/klinPr/compUse/Tabellenamely, the submission of an original IND application and the
amendment of an IND protocol approved previously. Each mecha-
nism is deﬁned by respective regulations. For the application of the
expanded access program, some requirementsmust be satisﬁed, i.e.
the patient is serious or life-threatening with no alternative ther-
apy, the potential patient beneﬁt must justify the potential risks,
and there must be no interference with market approval or po-
tential development [21 Code of Federal Regulations (CFR)
312.305]. Only the “Emergency Use IND/protocol” does not require
pre-approval in writing by the FDA, although it does require con-
tacting the agency via telephone for authorization.
The EU compassionate use programs are summarized in Table 2
[12e15]. We investigated three EU countriese France, Germany and
the UK. There is a common regulation (REGULATION (EC) No 726/
2004 Article 83) for a group of patients and a common EU directive
(DIRECTIVE 2001/83/EC Article 5) for individual patients [16].
Additionally, each country has regulations pertaining to their spe-
ciﬁc country. In France, there are two categories of compassionateGermany (BfArM) UK (MHRA)
Compassionate Use Specials
.
ic
Ordinance on the placing
on the market of
unauthorized medicinal
products for compassionate
use.
 Regulation 170 of The Human
Medicines Regulations 2012.
 The supply of unlicensed medicinal
products (“specials”) MHRA
Guidance Note 14.
o
e
 REGULATION (EC) No
726/2004 Article 83
 The 14th amendment of
the German Medicines
Act (Updated by the 15th
amendment in July 2009)
 DIRECTIVE 2001/83/EC Article 5
 Regulations 1994 (SI 1994/3144)
 Regulations 2005 (SI 2005/2789)
 Regulations 2012 (SI 2012/1916)
f
s.
a
e
d
/
1) Not for single patient.
2) Not licensed in member
state of the EU/EEA.
3) Serious debilitating or
life-threatening disease.
4) The patients are not
satisfactorily treated by
a medicinal product
authorized in Germany.
5) Application either at
EMA or any other
Member State of EU/
EEA.
1) In response to an unsolicited order.
2) Manufactured and assembled in
accordance with the speciﬁcation of
a person who is a doctor, dentist,
nurse independent prescriber,
pharmacist independent prescriber
or supplementary prescriber.
3) For use by a patient for whose
treatment that person is directly
responsible in order to fulﬁl the
special needs of that patient; and
meets the conditions speciﬁed in
regulation 167(2)-(8).
Group Individual patient
Not described Not described
Required Required
Free of charge Country (the National Health Service in
Part VIIIB of Drug Tariff).
Zanamivir i.v (Zanamavir) Modaﬁnil (as an example of “Specials”)
es Agency, ANSM: French National Agency for Medicines and Health Products Safety,
eimittel und Medizinprodukte), UK: United Kingdom, MHRA: The Medicines and
emporary Authorizations for Use).
U). ANSM 2015. http://ansm.sante.fr/var/ansm_site/storage/original/application/
_eng.pdf.
.html.
/AMHV-Flow-chart.pdf?__blob¼publicationFile&v¼3.
ﬁle/373505/The_supply_of_unlicensed_medicinal_products__specials_.pdf.
201.aspx; http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx; http://www.
(Part VIIB).
/ATU_nominatives_Annee2014_2.xls.
ATU/ATU-de-cohorte-en-cours/(offset)/5#paragraph_17967.
/_node.html.
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Utilisation e Temporary Authorizations for Use)” and “Cohort ATU”.
In contrast, the other countries have one compassionate use
program for either individual patients or a group of patients.
3.1.1. The cost of unapproved drugs
In the US, a sponsor, who takes responsibility for and initiates a
clinical investigation (e.g., an individual or pharmaceutical company,
governmental agency, academic institution, private organization, or
other organizations), is permitted to charge patients for the costs
under the requirement of charging the FDA for the expanded access
program (21 CFR 312.8). In the EU, for example France has a rule that
sponsors may request the country to support the costs [12].
3.1.2. Compassionate use mechanisms in the drug development
phase
Fig. 1 shows the mechanism that can be applied to the drug
development phase of the cycle, referring to “when can it be used”
in Tables 1 and 2. In the US, the “Emergency Use” and “Individual
Patients” mechanisms are applicable to all phases. In contrast,
“Intermediate-Size Patients” and “Treatment IND/Protocol” mech-
anisms are used during the clinical trial or after the clinical trial
phase.
3.2. Overview of the compassionate use of medical devices
The FDA expanded access programs for devices are summarized
in Table 3 [17e19]. There are four categories of medical device
expanded programs that depend on the urgency, the number of
patients, when it can be used, and whether prior FDA approval is
required.
The “Emergency Use”mechanism is used for individual patients
[21 CFR 812.35(a)]. The following criteria must be satisﬁed: (1) the
patient has a life-threatening condition; (2) there is no alternative
therapy; and (3) there is no time to obtain FDA approval in advance.Fig. 1. Compassionate use by phase and application size for drugs. The US: The United Sta
Temporaire d' Utilisation (Temporary Authorizations for Use). Source: 21 CFR 312 Subpart
storage/original/application/cadfbcf9594614d59c8915670853a28b.pdf.Another mechanism for individual patients is “Compassionate Use
(Individual Patient Access)”, which is used for an individual patient
or a small group of patients [21 CFR 812.35(a)]. The following
criteria must be satisﬁed in this case: (1) the patient(s) has a serious
disease or condition; and (2) there is no alternate therapy. Pre-
approval of the FDA is required to use this mechanism. Another
mechanism is the “Treatment Investigational Device Exemption
(IDE)” (21 CFR 812.36). This is a wide access mechanism. The
number of patients whom the product is applied to is dependent on
a patient or physician's need. This mechanism can also be used
during the clinical trial phase. Its criteria are as follows: (1) the
patients have life-threatening or serious disease; (2) no alternate
therapy is available; (3) a controlled clinical trial for the device is in
progress; and (4) the sponsor is pursuing market approval. The last
mechanism is “Continued Access.” This mechanism is for patients
who did not join a clinical trial for the device, and it is assumed that
it should be applied after the clinical trial is complete. Its criteria are
public health need or preliminary evidence of the effectiveness of
the device without signiﬁcant safety concerns. Pre-FDA approval is
required for this mechanism. The number of patients able to apply
is the same as the number enrolled in the clinical trial; therefore,
the same population of the pivotal trial is included.
In the EU, there is no related mechanism because Conformite
Europeenne (CE) marking needs to be afﬁxed before all medical
devices are used.
3.2.1. The cost of unapproved medical devices
The US Investigational Device Exemption (IDE) regulations
permit sponsors to charge for an investigational device; however, the
charge should not exceed the amount that is necessary to cover the
costs of the manufacturing, research, development, and handling of
the investigational device [21 CFR 812.7(b)]. Sponsors need to justify
the proposed charges for the device in the IDE application, states the
amount to be charged, and explains why the charge does not
constitute commercialization [21 CFR 812.20(b)(8)] [20].tes, The EU: the European Union, IND: Investigational New Drug, ATU: Authorisation
I and Notice to applicants for marketing for ATU: http://ansm.sante.fr/var/ansm_site/
Table 3
The FDA's expanded access mechanism for devices.
Category Emergency Use Compassionate Use
(Individual Patient Access)
Treatment IDE Continued Access
Regulation 21 CFR 812.35(a)
“Guidance for the
Emergency Use of
Unapproved Medical
Devices”
50 FR 42866
21 CFR 812.35(a) 21 CFR 812.36
62 FR 48940
IDE Memorandum #D96-1
Safety reporting regulation 21 CFR 812.150 21 CFR 812.150 21 CFR 812.150 21 CFR 812.150
Criteria 1) Life-threatening or
serious disease or
condition.
2) No alternative.
3) No time to obtain FDA
approval.
1) Serious disease or
condition.
2) No alternative.
1) Life-threatening or
serious disease.
2) No alternative.
3) Controlled clinical trial.
4) Sponsor pursuing
marketing approval.
1) Public health need or
preliminary evidence
that the device will be
effective and there are
no signiﬁcant safety
concerns.
Population Limited to few patients Individual patient or small
groups of patients
Wide access; depends on
patient/physician need
The same patient
population as pivotal trial
When can it be used Before or after initiation of
clinical trial
During clinical trial During clinical trial or all
clinical trials are complete
After completion of clinical
trial
Prior the FDA approval Not required (it shall be
reported to FDA within 5-
working days)
Required Required Required
Charge Patienta or donation by
company
Patient or donation by
company
Patient or donation by
company
Patient or donation by
company
Example of products
(ClinicalTrials.gov
identiﬁer)
AMPLATZER™ Muscular
VSD Occluder
(NCT00590382)
AMPLATZER™ Muscular
VSD Occluder
(NCT00590382)
DERMAGRAFT® (not
applicable)
EXCOR® Pediatric
Ventricular Assist Device
(NCT01242891)
Example of products of
which data from
compassionate use cases
are employed in
approval review reports
(premarket approval
number or humanitarian
device exemption
number)
 Relay® Thoracic Stent-Graft with Plus Delivery System (P110038).
 Syncardia temporary CardioWest™ Total Artiﬁcial Heart (TAH-t) (P030011).
 EXCOR® Pediatric Ventricular Assist Device (H100004).
The US: The United States, CFR: Code of Federal Regulation, FDA: Food and Drug Administration, IDE: Investigational Device Exemptions.
Source: http://www.fda.gov/RegulatoryInformation/Guidances/ucm126427.htm.
Source: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm051345.htm.
Source: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080202.htm#III.
Source: Guidance on IDE Policies and Procedures.
ClinicalTrials.gov by the U.S. National Institutes of Health https://clinicaltrials.gov/.
DERMAGRAFT® Treatment IDE source: http://www.accessdata.fda.gov/cdrh_docs/pdf/P000036b.pdf.
Relay® Thoracic Stent-Graft with Plus Delivery System (P110038) source: http://www.accessdata.fda.gov/cdrh_docs/pdf11/P110038b.pdf.
Syncardia temporary CardioWest™ Total Artiﬁcial Heart (TAH-t) (P030011) source: http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030011b.pdf.
EXCOR® Pediatric Ventricular Assist Device (H100004) source: http://www.accessdata.fda.gov/cdrh_docs/pdf10/H100004b.pdf.
Barostim neo® Legacy System (H130007) source: http://www.accessdata.fda.gov/cdrh_docs/pdf13/H130007b.pdf.
a The charge should not exceed an amount necessary to recover the costs of manufacture, research, development, and handling of the investigational device [21 CFR
812.7(b)].
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development phase
Fig. 2 shows the mechanism to be applied in each phase of the
medical device development cycle, referring to “When can it be
used” in Table 3. In the US, the “Emergency Use” mechanism is
applied to all phases. In contrast, the “Compassionate Use (Indi-
vidual Patient Access),” “Treatment Use” and “Continues Access”
mechanisms are applied during or after clinical trials.
3.3. Mechanisms for unapproved biologics in the US and the EU
Table 4 summarizes the mechanisms for unapproved biologics,
including human cells and tissue products, in the US and the EU.
The US applies the same mechanism used for drugs and the EU has
a standalone mechanism, Advanced Therapy Medicinal Product
(ATMP) [21].
3.4. The number of expanded access and compassionate use cases
Fig. 3 shows the number of FDA expanded access program cases
for drugs approved between 2010 and 2013. The total number ofsubmissions in each year is between 936 and 1,199. The four-year
total for the “Emergency Use IND/Protocol” accounted for 37.5%
(1,547/4,123) of the total number of submissions. Both the “Emer-
gency Use IND/Protocol” and the “Single Patient Use IND/Protocol”
including “Emergency Use” accounted for 97.4% (4,017/4,123) of the
total number of submissions (Fig. 4).
Fig. 5 shows the number of FDA expanded access program cases
for vaccines, blood and biologics approved from 2010 to 2013.
Compared to 2010, the number of cases in 2013 increased by
approximately 205% (152/74) from 74 to 226. Of the four-year total,
“Emergency Use IND/Protocol” accounted for 44.4% (238/536). Both
the “Emergency Use IND/Protocol” and “Single Patient Use IND/
Protocol” including “Emergency Use” accounted for 95.0% (509/
536) of the total (Fig. 6).
3.5. Japan Advanced Medical Care B
There is no compassionate use mechanism in Japan, but there is
a program called “Advanced Medical Care B”, through which pa-
tients can access unapproved drugs or medical devices. The main
purpose of the program is to have the public insurance cover the
Fig. 2. Compassionate use by phase and application size for devices. The US: The United States, The EU: the European Union, IDE: Investigational Device Exemption. Source: http://
www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm051345.htm.
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products, which leads to the reduction of the patient's ﬁnancial
burden [2,22].
Japan will also be introducing a new mechanism under which
patients only have to cover the cost related to unapproved prod-
ucts, called a patient-requested cure system (kanjya moushide
ryouyou) [22].
Japan also plans to launch a new compassionate use program. It
will mainly be for patients who are interested in using unapprovedTable 4
Mechanisms for unapproved biologics in the US and the EU.
Category US FDA expanded access program
Regulation 21 CFR 312.305
21 CFR 312.310
21 CFR 312.315
21 CFR 312.320
Safety reporting regulation 21 CFR 312.32
Common criteria 1) The patient or patients to be treated have
life-threatening disease or condition, and t
or satisfactory alternative therapy to diagn
2) The potential patient beneﬁt justiﬁes th
treatment use and those potential risks are
the context of the disease or condition to b
3) Providing the investigational drug for the
interfere with the initiation, conduct, or co
investigations that could support marketin
expanded access use or otherwise compro
development of the expanded access use.
Population Based on each regulation of each mechanism
When can it be used Based on each regulation of each mechanism
Prior regulator approval Required
Examples of products
(ClinicalTrials.gov
identiﬁer)
GX-051 (NCT02079324)
The US: the United States, CFR: Code of Federal Regulation, FDA: Food and Drug Admini
ATMP Criteria Source: Flory E, Reinhardt J. European regulatory tools for advanced thera
000356364.
Source: ClinicalTrials.gov by the U.S. National Institutes of Health https://clinicaltrials.go
Source: DCVax-L <http://www.nwbio.com/nw-bio-announces-two-german-approvals-h
l-for-reimbursement/>.products but not able to join any clinical trials because of outside
criteria. This programwill enable patients to have improved access
to unapproved drugs as treatment options. In the scope of this
program, unapproved drugs will possibly include not only products
that other countries agencies' have approved but also products in
development in Japan. In this program, patients that do not meet
the inclusion criteria of clinical trials are able to use unapproved
products after the products' indication and usage or dosage and
administration are conﬁrmed [23].ATMP hospital exemption (EU)
Article 28 of Regulation 1394/2007
Article 28 of Regulation 1394/2007
a serious or immediately
here is no comparable
ose.
e potential risks of the
not unreasonable in
e treated.
requested use will not
mpletion of clinical
g approval of the
mise the potential
1) Preparation on a non-routine basis.
2) Preparation according to speciﬁc quality
standards (equivalent to those for
ATMPs with a centralized marketing
authorization).
3) Use within the same Member State.
4) Use in a hospital.
5) Use under the exclusive responsibility of
a medical practitioner.
6) Comply with an individual medical
prescription for a custom-made prod-
uct for an individual patient.
Individual patient
Before or after initiation of clinical trial
Required
DCVax-L (not applicable)
stration, the EU: the European Union, ATMP: Advanced Therapy Medicinal Product.
py medicinal products. Transfus Med Hemotherapy 2013;40:409e12. doi:10.1159/
v/.
ospital-exemption-for-early-access-program-with-dcvax-l-and-eligibility-of-dcvax-
Fig. 3. The number of FDA expanded access cases for drugs. 2010: reporting year
(October 13, 2009eOctober 12, 2010), 2011: reporting (October 13, 2010eOctober 12,
2011), 2012: ﬁscal year (October 1, 2011eSeptember 30, 2012), 2013: ﬁscal year
(October 1, 2012eSeptember 30, 2013). Source: http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
DrugandBiologicApprovalReports/INDActivityReports/ucm373560.htm (accessed
January 14, 2015).
Fig. 5. The number of FDA expanded access cases for biologics. 2010: reporting year
(October 13, 2009eOctober 12, 2010), 2011: reportingyear (October 13, 2010eOctober 12,
2011), 2012:ﬁscal year (October 1, 2011eSeptember30, 2012), 2013:ﬁscal year (October 1,
2012eSeptember 30, 2013). Source: http://www.fda.gov/biologicsbloodvaccines/
ucm413041.htm (accessed January 14, 2015).
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Expanded access and compassionate use programs are provided
from a humanitarian point of view. In contrast, pandemic cases
such as the recent Ebola virus outbreak are matters of national
security. The EU, US and Japan have options for emergency use
authorization in such crises (Article 5.2 of DIRECTIVE 2001/83/EC,
US Project Bioshield Act, and Article 23.2.8 Japanese Pharmaceu-
tical Affairs Act).
4. Discussion
In both the US and the EU, there are multiple mechanisms
depending on the urgency, the applicable phase or the number of
patients needing unapproved treatments. Additionally, the mech-
anisms cover all phases from before IND or IDE submission to
market authorization for the use of both unapproved drugs andFig. 4. The total number of FDA expanded access cases for drugs. Source: http://www.
fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
DrugandBiologicApprovalReports/INDActivityReports/ucm373560.htm (accessed
January 14, 2015).medical devices in the US. In contrast, only drugs have mechanisms
for compassionate use in the EU, and they are only applicable
during or after the clinical trials because some evidence is required
to conﬁrm the safety and efﬁcacy of the drugs. There is no
compassionate use program for medical devices in the EU because
CE marking is required before medical device products can be used.
For example, an assessment report of ChondroCelect® refers to
the results of compassionate use to indicate the safety of products
in their reports [24]. Additionally a summary of the safety and the
effectiveness data of the Relay® Thoracic Stent-Graft with Plus
Delivery System [25], Syncardia temporary CardioWest™ Total
Artiﬁcial Heart (TAH-t) [26], and EXCOR® Pediatric Ventricular
Assist Device [27] was provided (Table 3).
In clinical trials, there are two main categories: experimental
studies, including randomized controlled trials and controlled
clinical trials and observational studies including cohort and case
control studies. From an evidence level perspective, randomized
controlled trials provide the highest level of evidence, followed by
controlled clinical trials, cohort studies and case control studies.Fig. 6. The total number of FDA expanded access cases for biologics. Source: http://
www.fda.gov/biologicsbloodvaccines/ucm413041.htm (accessed January 14, 2015).
K. Tsuyuki et al. / Regenerative Therapy 4 (2016) 18e26 25From a methodological point of view, clinical trials are regarded as
the only means of obtaining reliable and interpretable efﬁcacy and
safety data of a medicinal product (EMEA/27170/2006). In princi-
ple, only approved drugs and medical devices should be used. To
obtain market authorization, we need to conduct experimental
studies such as clinical trials, including randomized controlled
trials and controlled clinical trials, which often provide high levels
of evidence. However, it is also important to have special mecha-
nisms such as compassionate use and expanded access in place for
the use of unapproved products to save patients with life-
threatening conditions. Recently, “Right to Try” laws were intro-
duced by some states in the US [9,28] so that patients could obtain
easy access to unapproved products. The data and results from the
use of unapproved products should be informative to evaluate
their safety and efﬁcacy which could help accelerate the market
approval and could reduce the number of patients needed in
clinical studies. Especially for cellular and tissue-based products,
the experiences of compassionate use should be quite informative,
because it is often difﬁcult to conduct a strict experimental study,
such as randomized controlled trials and controlled clinical trial,
and because non-clinical studies are not so predictive for their
safety and efﬁcacy.
In such cases, the results of an observational study are more
important than those of drug trials, and we can use the results from
compassionate use as a subtype of observational study.
Recently, some discussions have shown that observational
studies also provide reliable efﬁcacy and safety data [29,30]. As
shown in Fig. 3, there is not an increasing trend in FDA expanded
access cases for drugs; however, Fig. 5 shows an increasing trend in
FDA expanded access cases for vaccines, blood and biologics, as
more regenerative therapy products, such as human cells and tissue
products, enter the markets.
The following are considerations that address concerns
regarding the use of unapproved products.
A: It is difﬁcult for the local regulator to monitor the usage of
unapproved products.
The US and EU compassionate use mechanisms require
approval by regulators so that they will know which type of
products will be used under compassionate use and expanded
access programs. An approval process for the use of unapproved
products is required for regulators to monitor the use of unap-
proved products.
B: there is no information collected on the safety of these
products to protect patients.
The US regulations require a vigilance report on the adverse
events of approved products. That process helps regulators
collect safety information on unapproved products (e.g., for the
US, 21 CFR 312.32 for IND in Table 1, 21 CFR 812.150 for IDE in
Table 3). We need a clear process for reporting adverse events.
We could use an existing process for market-approved products
for unapproved products as well.
C: It is difﬁcult to assure the quality of the products.
The US expanded access submission requires a description of
the facility where the drug will be manufactured (21 CFR
312.305). Thus, if physicians and companies encounter any
quality issues with unapproved products, they are able to con-
tact the manufacturer. We need a similar traceability process.
We also need to ensure the quality of unapproved products
through mechanisms such as the Good Manufacturing Practice
(GMP) system.
D: It is difﬁcult for patients to obtain detailed information about
unapproved products and their availability.
Patients who are interested in joining compassionate use or
expanded access programs should be able to access thenecessary information to ﬁnd out which types of unapproved
products are available under these programs.
In the US, available unapproved products under the expanded
access programs are found on the U.S. National Institutes of
Health e ClinicalTrials.gov website [11]. Patients are able to
check the database and can ﬁnd information on any clinical trial
using unapproved products that they are interested in. However,
there is no strict rule for physicians to register in the database,
so the information is limited. We should share all of the
necessary informationwith patients who are interested in using
unapproved products.
E: It is not clear who should cover cost of unapproved products?
As shown in Tables 1 and 2, a provider of an unapproved
product, such as a pharmaceutical or medical device company,
may charge the patients for the cost of the unapproved product.
However, in some cases, the manufacturers should donate the
products for free because they have a life-saving compassionate
purpose. We need to develop a rule for unapproved products
that beneﬁts manufacturers for providing their products, even
for free. For example, in France, the country covers the cost of
unapproved products.5. Conclusion
There are various compassionate use-associated mechanisms
for both drugs and medical devices in the US and the EU. The main
purpose of these mechanisms is to save patients with life-
threatening conditions with no other approved alternative ther-
apy options. Another important beneﬁt could be to provide safety
and efﬁcacy information to support future market authorization.
However, there are some cases in which companies decline re-
quests from patients to provide unapproved products because they
want to avoid the risk of the use of products before conﬁrming their
efﬁcacy and safety in clinical trials. In these cases, companies are
criticized for not providing the products to patients with life-
threatening conditions [31,32]. We propose comprehensive mech-
anisms that consider the risks and beneﬁts to the patients inter-
ested in using unapproved products and the companies providing
the products.
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